mFluiDx
mFluiDx is developing a point-of-care molecular test called the “SIMPLE CHIP” that aims to provide PCR-equivalent results at a cost comparable to rapid antigen tests, enabling rapid, decentralized, on-site screening for multiple pathogens. The company is a UC Berkeley spin-out and is supported by various incubators and grants, with a mission to improve infectious disease diagnostics.
Industries
Nr. of Employees
small (1-50)
Products
Prototype disposable microfluidic diagnostic cartridge and reader
Prototype point-of-care diagnostic system composed of a disposable microfluidic cartridge and a reader instrument enabling automated, multiplexed nucleic acid testing with rapid turnaround.
Prototype disposable microfluidic diagnostic cartridge and reader
Prototype point-of-care diagnostic system composed of a disposable microfluidic cartridge and a reader instrument enabling automated, multiplexed nucleic acid testing with rapid turnaround.
Services
R&D service to develop integrated diagnostic prototypes consisting of disposable microfluidic cartridges and reader instruments for decentralized testing.
R&D service to develop integrated diagnostic prototypes consisting of disposable microfluidic cartridges and reader instruments for decentralized testing.
Expertise Areas
- Point-of-care molecular diagnostics development
- Microfluidic cartridge design and low-cost consumable manufacturing
- Multiplexed nucleic acid testing
- Sample-to-answer automation
Key Technologies
- Microfluidics
- Isothermal nucleic acid amplification
- Multiplexed nucleic acid detection
- Disposable cartridge + reader instrument architecture
News & Updates
A publication in Science Advances describing the SIMPLE CHIP technology for molecular testing of bacteria, viruses, DNA, and RNA.
Techcrunch Battlefield Finalist
mFluiDx was selected as one of the top 20 startups to pitch at Techcrunch Battlefield from a pool of 900 startups globally.
A publication in Science Advances describing the SIMPLE CHIP technology for molecular testing of bacteria, viruses, DNA, and RNA.
Techcrunch Battlefield Finalist
mFluiDx was selected as one of the top 20 startups to pitch at Techcrunch Battlefield from a pool of 900 startups globally.